文献速递眼底病与葡萄膜炎

TENAYA与LUCERNE:法瑞西单抗治疗新生血管性年龄相关性黄斑变性的3期试验第二年治疗延长给药结果

TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2.
PubMed 文献 · Ophthalmology · 2024-02-19

TENAYA和LUCERNE是两项设计相同的随机、双盲、活性对照3期非劣效试验,评估法瑞西单抗6.0 mg每16周一次对比阿柏西普2.0 mg每8周一次治疗初治新生血管性年龄相关性黄斑变性患者。两年时两组最佳矫正视力变化可比,多数患者达到延长给药间隔,眼部不良事件两组相当。

要点

  • 两年时法瑞西单抗与阿柏西普最佳矫正视力变化可比,TENAYA平均差异+0.4字母,LUCERNE平均差异-0.2字母。
  • 第112周时TENAYA和LUCERNE分别有59.0%和66.9%患者达到法瑞西单抗每16周给药,较第一年增加。
  • 第112周眼部不良事件两组相当,TENAYA为55.0%和56.5%,LUCERNE为52.9%和47.5%。

核心结论

  • 基于新生血管性年龄相关性黄斑变性疾病活动的治疗延长法瑞西单抗治疗在两年内维持了视力增益,大多数患者达到延长给药间隔。

研究设计与样本

  • TENAYA和LUCERNE为设计相同的随机、双盲、活性对照3期非劣效试验,纳入50岁及以上初治新生血管性年龄相关性黄斑变性患者。
  • 患者按1:1随机接受玻璃体腔内法瑞西单抗6.0 mg至多每16周一次或阿柏西普2.0 mg每8周一次。
  • 法瑞西单抗根据方案定义的疾病活动在第20周和第24周固定给药至第60周,第60周至第108周采用治疗延长个体化治疗间隔方案。

主要发现

  • 两年时最佳矫正视力较基线变化在TENAYA中法瑞西单抗组为+3.7字母(95%CI +2.1至+5.4),阿柏西普组为+3.3字母(95%CI +1.7至+4.9),平均差异+0.4字母(95%CI -1.9至+2.8)。
  • 两年时最佳矫正视力较基线变化在LUCERNE中法瑞西单抗组为+5.0字母(95%CI +3.4至+6.6),阿柏西普组为+5.2字母(95%CI +3.6至+6.8),平均差异-0.2字母(95%CI -2.4至+2.1)。
  • 第112周时TENAYA和LUCERNE分别有59.0%和66.9%患者达到法瑞西单抗每16周给药,较第一年增加;分别有74.1%和81.2%患者达到每12周或更长给药。
  • 截至第112周,研究眼眼部不良事件在TENAYA中法瑞西单抗组为55.0%、阿柏西普组为56.5%,在LUCERNE中分别为52.9%和47.5%。

关键数值与推荐

  • TENAYA和LUCERNE共治疗1326例患者,1113例(83.9%)完成治疗(法瑞西单抗n=555;阿柏西普n=558)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate 2-year efficacy, durability, and safety of the bispecific antibody faricimab, which inhibits both angiopoietin-2 and VEGF-A. DESIGN: TENAYA (ClinicalTrials.gov identifier, NCT03823287) and LUCERNE (ClinicalTrials.gov identifier, NCT03823300) were identically designed, randomized, double-masked, active comparator-controlled phase 3 noninferiority trials. PARTICIPANTS: Treatment-naive patients with neovascular age-related macular degeneration (nAMD) 50 years of age or older. METHODS: Patients were randomized (1:1) to intravitreal faricimab 6.0 mg up to every 16 weeks (Q16W) or aflibercept 2.0 mg every 8 weeks (Q8W). Faricimab fixed dosing based on protocol-defined disease activity at weeks 20 and 24 up to week 60, followed up to week 108 by a treat-and-extend personalized treatment interval regimen. MAIN OUTCOME MEASURES: Efficacy analyses included change in best-corrected visual acuity (BCVA) from baseline at 2 years (averaged over weeks 104, 108, and 112) and proportion of patients receiving Q16W, every 12 weeks (Q12W), and Q8W dosing at week 112 in the intention-to-treat population. Safety analyses included ocular adverse events (AEs) in the study eye through study end at week 112. RESULTS: Of 1326 patients treated across TENAYA/LUCERNE, 1113 (83.9%) completed treatment (n = 555 faricimab; n = 558 aflibercept). The BCVA change from baseline at 2 years was comparable between faricimab and aflibercept groups in TENAYA (adjusted mean change, +3.7 letters [95% confidence interval (CI), +2.1 to +5.4] and +3.3 letters [95% CI, +1.7 to +4.9], respectively; mean difference, +0.4 letters [95% CI, -1.9 to +2.8]) and LUCERNE (adjusted mean change, +5.0 letters [95% CI, +3.4 to +6.6] and +5.2 letters [95% CI, +3.6 to +6.8], respectively; mean difference, -0.2 letters [95% CI, -2.4 to +2.1]). At week 112 in TENAYA and LUCERNE, 59.0% and 66.9%, respectively, achieved Q16W faricimab dosing, increasing from year 1, and 74.1% and 81.2%, achieved Q12W or longer dosing. Ocular AEs in the study eye were comparable between faricimab and aflibercept groups in TENAYA (55.0% and 56.5% of patients, respectively) and LUCERNE (52.9% and 47.5% of patients, respectively) through week 112. CONCLUSIONS: Treat-and-extend faricimab treatment based on nAMD disease activity maintained vision gains through year 2, with most patients achieving extended dosing intervals. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Khanani AM, Kotecha A, Chang A, et al. TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2. Ophthalmology. 2024. PMID: 38382813. doi:10.1016/j.ophtha.2024.02.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。